CY1109352T1 - Παραγωγα 1-(4-αμινο-κυκλοεξυλ)-1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου - Google Patents

Παραγωγα 1-(4-αμινο-κυκλοεξυλ)-1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου

Info

Publication number
CY1109352T1
CY1109352T1 CY20091100940T CY091100940T CY1109352T1 CY 1109352 T1 CY1109352 T1 CY 1109352T1 CY 20091100940 T CY20091100940 T CY 20091100940T CY 091100940 T CY091100940 T CY 091100940T CY 1109352 T1 CY1109352 T1 CY 1109352T1
Authority
CY
Cyprus
Prior art keywords
agents
modulators
compounds
control
present
Prior art date
Application number
CY20091100940T
Other languages
English (en)
Inventor
Qun Sun
Sam F. Victory
Zhengming Chen
R. Richard Goehring
John Whitehead
Sam Victory
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109352(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1109352T1 publication Critical patent/CY1109352T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Finishing Walls (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Ένα αντικείμενο ορισμένων ενσωματώσεων της παρούσας εφεύρεσης είναι η παροχή ενώσεων χρήσιμων ως αναλγητικά, αντιφλεγμονώδη, διουρητικά, αναισθητικά και ως νευροπροστατευτικοί παράγοντες, αντι-υπερτασικά, αντι-αγχολυτικά· ως παράγοντες ελέγχου της όρεξης· ως ρυθμιστές της ακοής· ως αντι-βηχικά, αντι-ασθματικά, ως διαμορφωτές της κινητικής δραστηριότητας, ως διαμορφωτές της εκμάθησης και της μνήμης, ως ρυθμιστές της έκλυσης νευροδιαβιβαστών και ορμονών, ως διαμορφωτές της νεφρικής λειτουργίας, ως αντικαταθλιπτικά, ως παράγοντες για τη θεραπεία της απώλειας της μνήμης λόγω νόσου του Αλτσχάιμερ ή άλλων ανοιών, ως αντιεπιληπτικά, αντισπασμωδικά, ως παράγοντες για τη θεραπεία της στέρησης από αλκοόλ και εθιστικές ουσίες, ως παράγοντες για τον έλεγχο του ισοζυγίου του ύδατος, ως παράγοντες για τον έλεγχο της απέκκρισης νατρίου και ως παράγοντες για τον έλεγχο διαταραχών της αρτηριακής πίεσης του αίματος και μεθόδων για τη χορήγηση των ρηθέντων ενώσεων. Οι ενώσεις της παρούσας εφεύρεσης είναι χρήσιμες για τη διαμόρφωση μιας φαρμακοδυναμικής απόκρισης από έναν ή περισσότερους οπιοειδείς υποδοχείς (ORL-1, μ, δ και κ) κεντρικώς ή/και περιφερικώς. Η απόκριση μπορεί να αποδοθεί στην ένωση που διεγείρει (αγωνιστής) ή αναστέλλει (ανταγωνιστής) τον ένα ή περισσότερους υποδοχείς. Ορισμένες ενώσεις μπορούν να διεγείρουν έναν υποδοχέα (π.χ., έναν μ αγωνιστή) και να αναστείλουν έναν διαφορετικό υποδοχέα (π.χ., έναν ανταγωνιστή του ORL-1). Η παρούσα εφεύρεση σε ορισμένες ενσωματώσεις περιλαμβάνει ενώσεις που έχουν το γενικό τύπο (III): όπου το D είναι μια 5-8μελής κυκλοαλκυλο, 5-8μελής ετεροκυκλική ή μια 6μελής αρωματική ή ετεροαρωματική ομάδα· οι άλλοι υποκαταστάτες ορίζονται στις αξιώσεις.
CY20091100940T 2001-04-18 2009-09-10 Παραγωγα 1-(4-αμινο-κυκλοεξυλ)-1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου CY1109352T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28466801P 2001-04-18 2001-04-18
US28466601P 2001-04-18 2001-04-18
US28466701P 2001-04-18 2001-04-18
US28466901P 2001-04-18 2001-04-18
EP02764236A EP1379246B1 (en) 2001-04-18 2002-04-18 Nociceptin analogs

Publications (1)

Publication Number Publication Date
CY1109352T1 true CY1109352T1 (el) 2012-05-23

Family

ID=27501377

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20091100010T CY1108707T1 (el) 2001-04-18 2009-01-08 Αναλογα νοσισεπτινης
CY20091100475T CY1109053T1 (el) 2001-04-18 2009-04-29 Παραγωγα 1-(4-πιπεριδινυλ)-1,3-διυδρο-2η-ινδολο-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου
CY20091100552T CY1109092T1 (el) 2001-04-18 2009-05-22 Παραγωγα 1-(4-πιπεριδινυλ)-1,3-διυδρο-2η-βενζοξαζολο-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου
CY20091100940T CY1109352T1 (el) 2001-04-18 2009-09-10 Παραγωγα 1-(4-αμινο-κυκλοεξυλ)-1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20091100010T CY1108707T1 (el) 2001-04-18 2009-01-08 Αναλογα νοσισεπτινης
CY20091100475T CY1109053T1 (el) 2001-04-18 2009-04-29 Παραγωγα 1-(4-πιπεριδινυλ)-1,3-διυδρο-2η-ινδολο-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου
CY20091100552T CY1109092T1 (el) 2001-04-18 2009-05-22 Παραγωγα 1-(4-πιπεριδινυλ)-1,3-διυδρο-2η-βενζοξαζολο-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου

Country Status (26)

Country Link
US (4) US6867222B2 (el)
EP (7) EP1598339B1 (el)
JP (4) JP4364513B2 (el)
KR (2) KR100847296B1 (el)
CN (1) CN100352816C (el)
AT (4) ATE410165T1 (el)
AU (1) AU2002307416B2 (el)
BR (1) BR0209129A (el)
CA (1) CA2444198C (el)
CL (2) CL2009001278A1 (el)
CY (4) CY1108707T1 (el)
CZ (1) CZ20032850A3 (el)
DE (4) DE60229224D1 (el)
DK (4) DK1598340T3 (el)
ES (4) ES2315394T3 (el)
HK (4) HK1088891A1 (el)
HU (1) HUP0401109A3 (el)
IL (4) IL158484A0 (el)
MX (1) MXPA03009600A (el)
NO (1) NO20034661L (el)
NZ (5) NZ551453A (el)
PL (1) PL367310A1 (el)
PT (4) PT1379246E (el)
SI (4) SI1598339T1 (el)
WO (1) WO2002085357A1 (el)
YU (1) YU82303A (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6615189B1 (en) * 1998-06-22 2003-09-02 Bank One, Delaware, National Association Debit purchasing of stored value card for use by and/or delivery to others
DE60229224D1 (de) 2001-04-18 2008-11-20 Euro Celtique Sa Nociceptin-analoga
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
WO2004064835A1 (en) * 2003-01-17 2004-08-05 Neurosearch A/S Use of ion channel modulating agents for treating pain
CA2516931C (en) 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
JP2007520493A (ja) * 2004-02-03 2007-07-26 ユーロ−セルティーク エス．エイ． シアノイミノベンゾイミダゾールの合成
JPWO2006080519A1 (ja) * 2005-01-31 2008-06-19 協和醗酵工業株式会社 ジアミン誘導体
ATE429428T1 (de) * 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
EP1983992A4 (en) * 2006-01-19 2010-08-18 Abbott Lab 2-IMINO-BENZIMIDAZOLES
US8354434B2 (en) * 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080287479A1 (en) * 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
KR101227072B1 (ko) * 2007-01-16 2013-01-29 시오노기세이야쿠가부시키가이샤 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
CA2679530C (en) * 2007-03-01 2012-09-25 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
MX2010002449A (es) 2007-08-31 2010-09-07 Purdue Pharma Lp Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos.
RU2010114035A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
WO2010010458A1 (en) 2008-07-21 2010-01-28 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
CA2787063C (en) 2010-01-11 2018-11-27 Astraea Therapeutics, Llc Nicotinic acetylcholine receptor modulators
CA2852796A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
CA2896871A1 (en) * 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
US10112924B2 (en) * 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171360A (en) * 1875-12-21 Improvement in mortising-machines
US49212A (en) * 1865-08-08 Improvement in submerged force-pumps
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3325499A (en) * 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
US3325490A (en) * 1965-02-23 1967-06-13 Rexall Drug Chemical Substituted 1-hydroxydibenzopyrans
DE2609645A1 (de) 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
EP0029707B1 (en) * 1979-11-21 1984-02-01 Kyowa Hakko Kogyo Co., Ltd Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4410528A (en) * 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
DE3827641A1 (de) * 1988-08-16 1990-03-08 Basf Ag 2,6-polyalkylpiperidinsubstituierte bislactame und deren verwendung zum stabilisieren von organischem material, insbesondere von kunststoffen und damit stabilisiertes material
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE216580T1 (de) * 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
JPH09512016A (ja) * 1994-04-14 1997-12-02 メルク エンド カンパニー インコーポレーテッド α１Ｃアドレナリン受容体拮抗薬
FR2722190B1 (fr) * 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
WO1996013262A1 (en) * 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
GB9603457D0 (el) * 1996-02-19 1996-04-17 Merck & Co Inc
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
WO1996041626A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
CA2231773A1 (en) 1995-09-13 1997-03-20 Shigeru Aono Phenylpiperidine derivative
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
PL329053A1 (en) * 1996-03-30 1999-03-01 Roche Diagnostics Gmbh Novel derivatives of oxazolydine, method of obtaining them and therapeutic agents containing such compounds
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038665A2 (en) * 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE341542T1 (de) 1996-04-19 2006-10-15 Neurosearch As 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität
NZ334543A (en) * 1996-09-10 2000-06-23 Thomae Gmbh Dr K Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998032439A1 (en) 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6063796A (en) * 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
JP4366532B2 (ja) * 1997-05-30 2009-11-18 萬有製薬株式会社 ２−オキソイミダゾール誘導体
JPH10330377A (ja) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
JP2001526178A (ja) * 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
WO1999032481A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999036421A1 (en) * 1998-01-19 1999-07-22 Pfizer Pharmaceuticals Inc. 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제
BR9909666A (pt) 1998-03-26 2001-09-11 Japan Tobacco Inc Derivados de amida e antagonistas de nociceptina
EP1080091A1 (en) 1998-05-18 2001-03-07 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
WO2000013508A1 (en) 1998-09-09 2000-03-16 Ishihara Sangyo Kaisha, Ltd. Fused-benzene derivatives useful as herbicides
AR021968A1 (es) 1998-12-23 2002-09-04 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
US6204265B1 (en) 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
WO2000038720A1 (fr) * 1998-12-24 2000-07-06 Meiji Seika Kaisha, Ltd. Remedes contre la douleur
JP4011819B2 (ja) * 1999-04-12 2007-11-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 インドール誘導体の製造法およびその中間体
CA2341542A1 (en) 1999-06-24 2000-12-28 Toray Industries, Inc. .alpha.1b-adrenergic receptor antagonists
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
MXPA02000340A (es) * 1999-07-21 2002-06-21 Fujisawa Pharmaceutical Co Derivados de benzimidazolona y su uso como inhibidores fosfodiesterasa.
WO2001039775A1 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1122257B1 (en) 2000-01-05 2005-10-12 Pfizer Inc. Benzimidazole compounds as ORL1-receptor agonists
WO2001060796A1 (en) * 2000-02-18 2001-08-23 Meiji Seika Kaisha, Ltd. PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS
WO2001068604A2 (en) * 2000-03-14 2001-09-20 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
EP1277737A4 (en) * 2000-03-24 2003-05-07 Meiji Seika Kaisha DIPHENYLALKYLAMINE DERIVATIVES AS AGONISTS OF THE OPIOID -g (d) RECEPTOR
DE60135457D1 (de) 2000-05-29 2008-10-02 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung von stickstoffverbindungen
EP1167969A2 (en) 2000-06-14 2002-01-02 Pfizer Inc. Method and system for predicting pharmacokinetic properties
MXPA03001422A (es) * 2000-08-14 2004-01-26 Johnson & Johnson Pirazoles substituidos.
CN1212839C (zh) * 2000-09-06 2005-08-03 奥索-麦克尼尔药品公司 取代的吡唑在制备用于治疗变态反应的药物方面的用途
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
AR035230A1 (es) * 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
DE60229224D1 (de) * 2001-04-18 2008-11-20 Euro Celtique Sa Nociceptin-analoga
EP1614680B1 (en) 2001-04-19 2011-12-21 Eisai R&D Management Co., Ltd. Process for preparing 2-iminopyrrolidine derivatives
DE60226161T2 (de) 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE

Also Published As

Publication number Publication date
CY1109092T1 (el) 2014-07-02
PT1598340E (pt) 2009-04-13
ES2322158T3 (es) 2009-06-17
PL367310A1 (en) 2005-02-21
IL208907A0 (en) 2011-01-31
DK1598339T3 (da) 2009-09-28
IL158484A0 (en) 2004-05-12
EP1379246B1 (en) 2008-10-08
PT1598339E (pt) 2009-09-03
NO20034661D0 (no) 2003-10-17
YU82303A (sh) 2006-03-03
JP5081870B2 (ja) 2012-11-28
DK1598338T5 (da) 2010-01-18
EP1918279A3 (en) 2008-07-16
US20050159452A1 (en) 2005-07-21
BR0209129A (pt) 2005-12-20
DE60231257D1 (de) 2009-04-02
CL2009001278A1 (es) 2009-10-09
MXPA03009600A (es) 2004-04-02
KR100878774B1 (ko) 2009-01-14
DK1379246T3 (da) 2009-01-26
EP1598338B1 (en) 2009-02-18
HK1088891A1 (en) 2006-11-17
KR100847296B1 (ko) 2008-07-23
CY1109053T1 (el) 2014-07-02
HK1063149A1 (en) 2004-12-17
NZ528977A (en) 2005-10-28
WO2002085357A1 (en) 2002-10-31
DE60229224D1 (de) 2008-11-20
JP5189562B2 (ja) 2013-04-24
EP1598340A1 (en) 2005-11-23
HK1086000A1 (en) 2006-09-08
SI1598339T1 (sl) 2009-12-31
CL2009001279A1 (es) 2009-11-27
PT1379246E (pt) 2009-01-14
JP2009263380A (ja) 2009-11-12
US20030069249A1 (en) 2003-04-10
US6867222B2 (en) 2005-03-15
US20090156640A1 (en) 2009-06-18
CN100352816C (zh) 2007-12-05
EP1930322A1 (en) 2008-06-11
CA2444198A1 (en) 2002-10-31
NZ540235A (en) 2007-01-26
ATE424385T1 (de) 2009-03-15
EP1379246A4 (en) 2005-09-28
SI1598338T1 (sl) 2009-06-30
US7495109B2 (en) 2009-02-24
EP1598338B9 (en) 2009-11-18
JP2005518330A (ja) 2005-06-23
JP2009263378A (ja) 2009-11-12
HUP0401109A3 (en) 2007-12-28
EP1918279A2 (en) 2008-05-07
DE60231442D1 (de) 2009-04-16
IL208907A (en) 2012-09-24
IL158484A (en) 2010-12-30
DE60232752D1 (de) 2009-08-06
CZ20032850A3 (cs) 2004-02-18
NZ540233A (en) 2007-02-23
JP4364513B2 (ja) 2009-11-18
US20120095049A1 (en) 2012-04-19
EP1598339B1 (en) 2009-06-24
CY1108707T1 (el) 2014-04-09
AU2002307416B2 (en) 2005-08-11
NZ551453A (en) 2008-02-29
ATE410165T1 (de) 2008-10-15
HK1088892A1 (en) 2006-11-17
SI1379246T1 (sl) 2009-04-30
EP1379246A1 (en) 2004-01-14
NO20034661L (no) 2003-12-17
SI1598340T1 (sl) 2009-08-31
CN1561211A (zh) 2005-01-05
EP2050450A1 (en) 2009-04-22
US8252815B2 (en) 2012-08-28
JP2009263379A (ja) 2009-11-12
KR20060127421A (ko) 2006-12-12
ATE434607T1 (de) 2009-07-15
US7939670B2 (en) 2011-05-10
EP1598340B1 (en) 2009-03-04
CA2444198C (en) 2010-06-22
ES2315394T3 (es) 2009-04-01
DK1598338T3 (da) 2009-06-08
IL208903A (en) 2012-07-31
ES2323876T3 (es) 2009-07-27
ES2329252T3 (es) 2009-11-24
EP1598338A1 (en) 2005-11-23
DK1598340T3 (da) 2009-05-11
NZ540234A (en) 2007-01-26
KR20030096328A (ko) 2003-12-24
PT1598338E (pt) 2009-05-08
EP1598339A1 (en) 2005-11-23
IL208903A0 (en) 2011-01-31
HUP0401109A2 (hu) 2004-09-28
ATE423098T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
CY1109352T1 (el) Παραγωγα 1-(4-αμινο-κυκλοεξυλ)-1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης και σχετικες ενωσεις ως αναλογα νοσισεπτινης και προσδεματα orl1 για τη θεραπευτικη αγωγη του πονου
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
CY1105341T1 (el) Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
CY1106784T1 (el) Υποκατεστημενα παραγωγα φαινυλ προπιονικου οξεος ως συναγωνιστες του ανθρωπινου υπεροξυσωματικου πολλαπλασιαστη - ενεργοποιημενου υποδοχεα αλφα (ppar)
JP2004512328A5 (el)
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
TR200102233T2 (tr) İndol türevleri ve bunların MCP-1 antagonistleri olarak kullanımı.
BR9609717A (pt) Administração epidural de compostos terapêuticos com sustentada taxa de liberação
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
DE60322680D1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
PT779284E (pt) Novos derivados de 2-naftamidas e suas aplicacoes terapeuticas como agonistas dos receptores d3
NO20032261L (no) Medisinske preparater
IS1961B (is) Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
CY1107243T1 (el) Ανταγωνιστες χημειοκινικων υποδοχεων και μεθοδοι χρησης τους
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo